MTNB — Matinas BioPharma Holdings Cashflow Statement
0.000.00%
Last trade - 00:00- $3.10m
- -$4.16m
Annual cashflow statement for Matinas BioPharma Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -22.4 | -23.3 | -21 | -22.9 | -24.3 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 5.3 | 6.25 | 6.27 | 5.6 | 8.21 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.509 | 1.53 | -4.79 | 1.67 | -0.131 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -17.4 | -15.2 | -19.2 | -15.3 | -15.9 |
| Capital Expenditures | -0.006 | -0.26 | -0.892 | -0.218 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -40.7 | 17 | 5.77 | 13.5 | 9.21 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -40.7 | 16.8 | 4.88 | 13.2 | 9.21 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 48 | 6.96 | 0.079 | -0.007 | 9.17 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -9.99 | 8.51 | -14.2 | -2.04 | 2.5 |